Bactiguard Holding AB (SE:BACTI.B)
:BACTI.B
Want to see SE:BACTI.B full AI Analyst Report?
Top Page
Bactiguard Holding AB
(BACTI.B)
Select Model
Select Model
Rating:50Neutral
Price Target:
kr18.00
▼(-6.74% Downside)
Action:ReiteratedDate:04/25/26
The score is primarily held back by weak financial performance (ongoing losses, declining TTM revenue, and negative free cash flow). Technical indicators provide a partial offset with constructive near-term momentum and price strength above key short/medium moving averages, but valuation remains challenging due to negative earnings and no indicated dividend support.
Positive Factors
Diversified revenue model: licensing + product sales
The dual model (royalties from BIP licensing plus branded product sales) provides durable revenue optionality. Licensing monetizes IP without full-scale manufacturing, enabling scalability and recurring royalty income while product sales preserve direct market presence and customer feedback loops.
Negative Factors
Persistent unprofitability
Ongoing net losses limit internal reinvestment and increase reliance on external financing for commercialization and R&D. Sustained unprofitability can pressure long-term strategic initiatives, raise dilution risk for shareholders, and constrain the company’s ability to scale global partnerships independently.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue model: licensing + product sales
The dual model (royalties from BIP licensing plus branded product sales) provides durable revenue optionality. Licensing monetizes IP without full-scale manufacturing, enabling scalability and recurring royalty income while product sales preserve direct market presence and customer feedback loops.
Read all positive factors
Bactiguard Holding AB (BACTI.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr646.56M
Dividend YieldN/A
Average Volume (3M)77.61K
Price to Earnings (P/E)―
Beta (1Y)0.14
Revenue Growth-10.66%
EPS Growth73.69%
CountrySE
Employees147
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.16
Shares Outstanding31,043,884
10 Day Avg. Volume120,571
30 Day Avg. Volume77,614
Financial Highlights & Ratios
PEG Ratio1.20
Price to Book (P/B)2.21
Price to Sales (P/S)3.23
P/FCF Ratio-96.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.13
Revenue Forecast (FY)kr217.50M
Bactiguard Holding AB Business Overview & Revenue Model
Company Description
Bactiguard Holding AB (publ), a medical device company, engages in the development and supply of infection prevention solutions in Sweden and internationally. Its infection prevention solutions reduce the risk of healthcare associated infections a...
How the Company Makes Money
Bactiguard makes money primarily through two revenue streams tied to its infection-prevention technology and product sales. (1) Technology licensing: Bactiguard licenses its BIP coating technology to medical device manufacturers, who incorporate t...
Bactiguard Holding AB Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
56
Neutral
Cash Flow
44
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 199.32M | 215.92M | 243.68M | 203.99M | 223.56M | 169.49M |
| Gross Profit | 83.31M | 184.65M | 207.71M | 139.98M | 180.14M | 130.80M |
| EBITDA | 41.04M | 45.15M | 24.99M | -89.98M | -543.00K | -5.94M |
| Net Income | -8.68M | -7.84M | -29.82M | -138.38M | -52.88M | -58.77M |
Balance Sheet | ||||||
| Total Assets | 537.34M | 545.06M | 655.91M | 662.17M | 807.70M | 849.29M |
| Cash, Cash Equivalents and Short-Term Investments | 35.34M | 44.26M | 116.73M | 123.22M | 197.73M | 217.59M |
| Total Debt | 161.30M | 162.92M | 227.77M | 233.10M | 238.70M | 247.96M |
| Total Liabilities | 225.74M | 230.13M | 327.57M | 309.00M | 311.99M | 307.84M |
| Stockholders Equity | 311.60M | 314.93M | 328.34M | 353.18M | 495.71M | 541.45M |
Cash Flow | ||||||
| Free Cash Flow | -3.26M | -7.21M | 10.21M | -60.94M | -7.86M | -38.00K |
| Operating Cash Flow | 3.19M | -1.49M | 24.99M | -52.33M | 3.06M | 7.26M |
| Investing Cash Flow | -6.45M | -5.72M | -14.78M | -8.61M | -10.92M | -7.29M |
| Financing Cash Flow | -9.07M | -62.74M | -21.20M | -11.84M | -13.89M | 205.83M |
Bactiguard Holding AB Technical Analysis
Positive
19.30
Price Trends
16.15
Positive
16.74
Positive
20.27
Negative
Market Momentum
0.31
Negative
57.17
Neutral
80.57
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BACTI.B, the sentiment is Positive. The current price of 19.3 is above the 20-day moving average (MA) of 16.65, above the 50-day MA of 16.15, and below the 200-day MA of 20.27, indicating a neutral trend. The MACD of 0.31 indicates Negative momentum. The RSI at 57.17 is Neutral, neither overbought nor oversold. The STOCH value of 80.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BACTI.B.
Bactiguard Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | kr840.80M | 103.06 | 6.93% | ― | -5.76% | -81.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr646.56M | -25.75 | -2.52% | ― | -10.66% | 73.69% | |
49 Neutral | kr1.03B | -61.68 | -4.42% | ― | 4.66% | 27.83% | |
48 Neutral | kr744.41M | -7.33 | -36.55% | ― | 48.53% | 17.86% | |
48 Neutral | kr209.08M | -5.27 | -18.55% | ― | 3.85% | -70.92% |
* Healthcare Sector Average
SE:BACTI.B
Bactiguard Holding AB
18.45
-13.55
-42.34%
SE:SEZI
Senzime AB
4.74
-0.36
-7.16%
SE:CRAD.B
C-Rad AB Class B
24.90
-6.55
-20.83%
SE:INTEG.B
Integrum AB Class B
7.84
-6.50
-45.31%
SE:SEDANA
Sedana Medical AB
10.32
-0.26
-2.46%
Bactiguard Holding AB Corporate Events
Bactiguard Absorbs Q1 Revenue Hit as Partnerships and Regulatory Push Underpin Growth Plan
Apr 23, 2026
Bactiguard reported first-quarter 2026 revenue of SEK 46.9 million, down 25% year on year, with net sales falling 28% and an operating loss widening to SEK 7.2 million, pressured by significant negative currency effects. Despite lower volumes, the...
Bactiguard Calls 2026 AGM, Proposes No Dividend and New Incentive Program
Apr 17, 2026
Bactiguard Holding AB has called its Annual General Meeting for 19 May 2026 in Stockholm, outlining participation rules for shareholders, including record date registration, notice requirements, and procedures for proxy representation and trustee-...
Bactiguard Sets 2030 Growth Targets as It Shifts to License-Based MedTech Model
Apr 16, 2026
Bactiguard is a global MedTech company specializing in infection prevention, primarily through an ultra-thin noble metal coating that prevents bacterial attachment and biofilm formation on medical devices. Its technology, validated over more than ...
Bactiguard Sets Audiocast for First-Quarter 2026 Results
Apr 15, 2026
Bactiguard Holding AB, the Stockholm-headquartered infection-prevention MedTech company, will publish its interim report for the first quarter of 2026 on 23 April at 07:00 CET. The group’s technology, based on an ultra-thin noble metal coati...
Bactiguard Nomination Committee Proposes Re-Election of Board and Chair for 2026 AGM
Apr 9, 2026
Bactiguard’s nomination committee has proposed the re-election of Thomas von Koch, Dr Richard Kuntz, Professor Anna Martling, Magdalena Persson and Jan Ståhlberg to the board ahead of the company’s Annual General Meeting on 19 May...
Bactiguard Delivers Strong Q4 as License Focus and Hydrocyn Growth Offset Weaker 2025 Sales
Feb 5, 2026
Bactiguard ended 2025 with a notably strong fourth quarter, posting a return to operating profit and higher EBITDA despite a full-year decline in revenue driven by currency headwinds and discontinued product lines. License revenues were stable exc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.